CN117487811A - 用于治疗与血管性血友病因子有关的并发症和疾病的组合物和方法 - Google Patents

用于治疗与血管性血友病因子有关的并发症和疾病的组合物和方法 Download PDF

Info

Publication number
CN117487811A
CN117487811A CN202311444936.9A CN202311444936A CN117487811A CN 117487811 A CN117487811 A CN 117487811A CN 202311444936 A CN202311444936 A CN 202311444936A CN 117487811 A CN117487811 A CN 117487811A
Authority
CN
China
Prior art keywords
vwf
aptamer
blood
von willebrand
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311444936.9A
Other languages
English (en)
Chinese (zh)
Inventor
朱曙灏
J·C·吉伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Band Therapeutics LLC
Original Assignee
Band Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Band Therapeutics LLC filed Critical Band Therapeutics LLC
Publication of CN117487811A publication Critical patent/CN117487811A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/316—Phosphonothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
CN202311444936.9A 2017-05-19 2018-05-18 用于治疗与血管性血友病因子有关的并发症和疾病的组合物和方法 Pending CN117487811A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762508530P 2017-05-19 2017-05-19
US62/508,530 2017-05-19
US201862638579P 2018-03-05 2018-03-05
US62/638,579 2018-03-05
PCT/US2018/033376 WO2018213697A1 (en) 2017-05-19 2018-05-18 Compositions and methods for the treatment of complications and disorders relating to von willebrand factor
CN201880012752.6A CN110520128B (zh) 2017-05-19 2018-05-18 用于治疗与血管性血友病因子有关的并发症和疾病的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880012752.6A Division CN110520128B (zh) 2017-05-19 2018-05-18 用于治疗与血管性血友病因子有关的并发症和疾病的组合物和方法

Publications (1)

Publication Number Publication Date
CN117487811A true CN117487811A (zh) 2024-02-02

Family

ID=64274836

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311444936.9A Pending CN117487811A (zh) 2017-05-19 2018-05-18 用于治疗与血管性血友病因子有关的并发症和疾病的组合物和方法
CN201880012752.6A Active CN110520128B (zh) 2017-05-19 2018-05-18 用于治疗与血管性血友病因子有关的并发症和疾病的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880012752.6A Active CN110520128B (zh) 2017-05-19 2018-05-18 用于治疗与血管性血友病因子有关的并发症和疾病的组合物和方法

Country Status (11)

Country Link
US (3) US11060094B2 (enExample)
EP (1) EP3624801A4 (enExample)
JP (2) JP7317805B2 (enExample)
KR (1) KR102830459B1 (enExample)
CN (2) CN117487811A (enExample)
AU (1) AU2018269935B2 (enExample)
CA (1) CA3058001A1 (enExample)
IL (1) IL269641B2 (enExample)
MX (1) MX390865B (enExample)
TW (1) TWI806868B (enExample)
WO (1) WO2018213697A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022015326A2 (pt) * 2020-02-04 2022-10-11 Takeda Pharmaceuticals Co Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante
US20230038761A1 (en) * 2020-02-04 2023-02-09 Band Therapeutics, Llc Regulation of von willebrand factor (vwf)
WO2022115502A1 (en) * 2020-11-24 2022-06-02 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
CN116723863A (zh) * 2020-11-24 2023-09-08 邦德治疗有限公司 用于治疗出血性病症的组合物和方法
US12090243B2 (en) 2021-03-24 2024-09-17 Aleo Bme, Inc. Compositions comprising fluid gels for tissue separation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512098A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US7563601B1 (en) * 2005-06-01 2009-07-21 City Of Hope Artificial riboswitch for controlling pre-mRNA splicing
WO2008066621A2 (en) * 2006-10-19 2008-06-05 Duke University Reversible platelet inhibition
WO2008150495A2 (en) 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
US20170044545A1 (en) * 2014-04-24 2017-02-16 Ribomic Inc. Aptamer for bonding to autotaxin and inhibiting biological activity of autotaxin, and use for same
EP3266871B1 (en) * 2015-03-06 2021-04-28 TAGCyx Biotechnologies Inc. Method for stabilizing dna aptamers
US10760083B2 (en) 2015-10-30 2020-09-01 Tagcyx Biotechnologies Inc. DNA aptamer that binds to vWF
US20230038761A1 (en) * 2020-02-04 2023-02-09 Band Therapeutics, Llc Regulation of von willebrand factor (vwf)
WO2022115502A1 (en) * 2020-11-24 2022-06-02 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
WO2023039522A1 (en) * 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Fatty acid conjugates of nucleic acids

Also Published As

Publication number Publication date
IL269641A (en) 2019-11-28
KR102830459B1 (ko) 2025-07-09
EP3624801A4 (en) 2021-02-24
RU2019136508A (ru) 2021-06-22
WO2018213697A1 (en) 2018-11-22
CN110520128B (zh) 2023-11-14
US20210292763A1 (en) 2021-09-23
TWI806868B (zh) 2023-07-01
JP7781815B2 (ja) 2025-12-08
AU2018269935A1 (en) 2019-11-28
EP3624801A1 (en) 2020-03-25
US20260092283A1 (en) 2026-04-02
AU2018269935B2 (en) 2024-05-16
US11060094B2 (en) 2021-07-13
JP2023093535A (ja) 2023-07-04
KR20200008122A (ko) 2020-01-23
TW201900877A (zh) 2019-01-01
RU2019136508A3 (enExample) 2022-02-14
NZ758741A (en) 2025-09-26
JP7317805B2 (ja) 2023-07-31
IL269641B2 (en) 2024-12-01
JP2020522566A (ja) 2020-07-30
CN110520128A (zh) 2019-11-29
IL269641B1 (en) 2024-08-01
MX390865B (es) 2025-03-12
US20200165612A1 (en) 2020-05-28
CA3058001A1 (en) 2018-11-22
MX2019013700A (es) 2020-01-15

Similar Documents

Publication Publication Date Title
JP7781815B2 (ja) フォン・ヴィレブランド因子に関連する合併症及び障害の処置のための組成物及び方法
US20090203766A1 (en) vWF aptamer formulations and methods for use
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
US20230038761A1 (en) Regulation of von willebrand factor (vwf)
US11723913B2 (en) Use of specific siRNA against protein S for the treatment of hemophilia
RU2806844C2 (ru) Композиции и способы лечения осложнений и нарушений, связанных с фактором фон виллебранда
US11820971B2 (en) Nucleic acids for inhibiting expression of PROS1 in a cell
US20220243202A1 (en) Nucleic acids for inhibiting expression of pros1 in a cell
WO2022096424A1 (en) Nucleic acids for inhibiting expression of pros1 in a cell
Ferrari et al. Potential Clinical Use of Recombinant Human ADAMTS13
HK40034310A (en) Use of specific sirna against protein s for the treatment of hemophilia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination